###### Strengths and limitations of this study

-   This is the first study to assess the analgesic efficacy of duloxetine in patients suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, and the results of the trial will clarify the second-line standard treatment for cancer-related neuropathic cancer pain.

-   This is an adequately powered study to provide a clinically meaningful outcome, and adverse effects following interventions will be systematically evaluated.

-   We excluded patients with depression from the study population for accurate evaluation of the pharmacological effects of duloxetine on pain.

-   This study includes the heterogeneity of causes of neuropathic cancer pain.

-   The primary endpoint is not worst pain intensity in the last 24 hours but the difference in average pain intensity score at T3 (day 10) between two groups.

Introduction {#s1}
============

Pain is a symptom that is experienced by many patients with cancer. Prevalence at the time of diagnosis is 30%, and this increases to 90% in advanced stages.[@R1] Pain in patients with cancer is often classified as nociceptive pain or neuropathic pain (NP), but both types are thought to be intermixed. Of patients with cancer-related pain, 33% have NP.[@R1] In general, NP is often resistant to treatment, whereas nociceptive pain tends to respond well to treatment.[@R2]

The efficacy of many drugs for NP has been reported in patients with non-cancer disease, and some have been shown to be effective for NP in patients with cancer.[@R6] These drugs include opioids, tricyclic antidepressants (TCAs) and gabapentinoids (gabapentin and pregabalin).[@R7]

In patients with cancer, the efficacy of TCAs and gabapentinoids has been proven in clinical trials,[@R12] and a phase III study revealed moderate analgesic effects of gabapentin in combination with opioids.[@R14] However, it is unclear which drug is most effective in cases in which first-line treatment with gabapentinoids fails to alleviate NP in patients with cancer.

In treatment of non-cancer NP, the efficacy of addition of duloxetine to pregabalin has been shown in a phase III study.[@R15] There is, however, no empirical data for second-line treatment of NP in patients with cancer. The National Comprehensive Cancer Network guidelines list duloxetine as a potential choice for second-line treatment,[@R8] and a phase III study showed the efficacy of duloxetine in treatment of chemotherapy-induced peripheral neuropathy (CIPN) in patients with cancer.[@R16] Furthermore, a small retrospective study reported the beneficial effects of duloxetine in palliation of NP refractory to pregabalin and opioids in 15 patients with cancer.[@R17] On the other hand, duloxetine has the potential for adverse events (AEs) such as dry mouth, sweating, fatigue, nausea, constipation, loss of appetite, dizziness, diarrhoea, hot flashes, hypertension, hyperhidrosis, palpitations, insomnia and drug--drug interactions as well as a risk of serotonergic syndrome and therefore should be used carefully.[@R18] According to a meta-analysis in 2015,[@R12] seven studies demonstrated clinical effects of duloxetine, but two studies revealed negative results.

In the double-blind, randomised, placebo-controlled study described here, we will evaluate the efficacy of addition of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids. Currently, there is no specific standard treatment for NP in patients with cancer; placebo is used instead of active control. The results of the trial will clarify the second-line standard treatment for cancer-related NP.

Methods and analysis {#s2}
====================

Study design {#s2a}
------------

The SPIRIT (Standard Protocol Items for Randomised Trials) statement and its checklist were followed in preparing the protocol. The study design is summarised in [figure 1](#F1){ref-type="fig"}. A multicentre, prospective, randomised, placebo-controlled, double-blinded, two-parallel group study will be performed to compare the efficacy of addition of duloxetine (intervention group) with the efficacy of addition of a placebo (control group).

![Flow chart of the procedures in the study. Participants will be randomised (1:1 allocation ratio) into the duloxetine intervention group or the placebo control group. Evaluations will be made at baseline (T0 randomization) and on day 0 (T1), day 3 (T2) and day 10 (T3). ECOG PS, European Cooperative Oncology Group Performance Status; EORTC, European Organisation for Research and Treatment of Cancer; HADS, Hospital Anxiety and Depression Scale; NRS, Numerical Rating Scale; SF-MPQ-2, Short-Form McGill Pain Questionnaire 2.](bmjopen-2017-017280f01){#F1}

Study settings and participants {#s2b}
-------------------------------

Recruiting will be performed in 14 adult palliative care sites across Japan, with involvement of 10 palliative care teams and 4 palliative care units. The inclusion and exclusion criteria are summarised in [box 1](#B1){ref-type="boxed-text"}.Box 1Inclusion and exclusion criteria**Inclusion criteria**Inpatients and outpatients with diagnoses of cancer and neuropathic painCurrently receiving opioidsUnresponsive or intolerant to gabapentinoids: (a) receiving doses of pregabalin of 300 mg/day or higher or gabapentin of 1800 mg/day or higher; (b) cannot receive increased doses of pregabalin or gabapentin due to side effectsNumerical Rating Scale pain score of 4 or higherHospital Anxiety and Depression Scale score \<20Age 20 years or olderCreatinine clearance rate ≥30 mL/min (Cockcroft-Gault formula)Serum aspartate aminotransferase \<100 IU/L, alanine aminotransferase \<100 IU/L and total bilirubin \<2.0 mg/dLExpected survival of 1 month or longer.­**Exclusion criteria**Chemotherapy-induced peripheral neuropathyProgressive paralytic symptomsContraindication for duloxetineTaking any type of antidepressantsA change in steroids, opioids, antidepressants, anticonvulsants, antipsychotic drugs, antiarrhythmic agents, or N-methyl-D-aspartate receptor antagonists within 2 days of initiation of administration of the study drug. Cases in which the patient has taken a hypnotic (including benzodiazepines such as zolpidem, zopiclone, eszopiclone, triazolam, ramelteon, suvorexant, brotizolam, flunitrazepam, rilmazafone and etizolam) as needed are not included.Drug misusers or patients who are addicted to drugs or have a history of addictionPatients with psychiatric disorders such as cognitive impairment who are unable to communicatePatients who are pregnant, breastfeeding or may possibly be pregnantOther patients who are determined to be inappropriate for participation in the study by the clinical investigator.

The main inclusion criterion is patients suffering from cancer pain (neuropathic or mixed) refractory to opioids and gabapentinoids. Diagnosis of NP is based on the International Association for the Study of Pain algorithm, in which a diagnosis of NP is made for patients with (1) pain with a distinct neuroanatomically plausible distribution, (2) a history suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system, (3) a range of pain that is neuroanatomically plausible and symptoms suggesting somatosensory injury or neurological disease (ie, hyperalgesia, hypoalgesia, dysesthesia or allodynia along the dermatome) and (4) relevant objective or imaging findings suggesting nervous system injury or disease (ie, imaging findings showing that a lesion is present). Based on these criteria, the certainty of the presence of NP is graded as definite NP (1 to 4 present) and probable NP (1 and 2, plus 3 or 4).[@R21] Definite and probable NP will be considered to indicate NP, and patients with these conditions will be eligible as subjects. Patients with an average Numerical Rating Scale (NRS) pain score in the preceding 24-hour period of 4 or higher[@R22] and those with total Hospital Anxiety and Depression Scale (HADS) scores of less than 20 will be included, based on criteria for pain intensity used in similar studies on NP.[@R23] The exclusion criteria are patients with progressive paralysis, a known contraindication to use of duloxetine, or depression. To examine the effects of duloxetine, we believe it is necessary to exclude patients with depression because duloxetine may alleviate pain through improving depression. Patients with CIPN or impaired cognitive function will also be excluded.

Recruitment, randomisation, masking and follow-up {#s2c}
-------------------------------------------------

### Recruitment {#s2c1}

Eligible patients satisfying the screening inclusion and exclusion criteria will be invited to participate in the study by site investigators.

### Randomisation {#s2c2}

Physicians will introduce the trial to patients. On enrolment and after providing informed consent, patients will be randomly allocated to intervention (duloxetine) or control (placebo) groups in a web-based central randomisation system using minimisation methods and a computer-generated randomisation schedule with a 1:1 allocation ratio. In performing this allocation, we will minimise the following adjustment factors to avoid a large bias: (1) average pain intensity measured by the NRS in the last 24 hours (≤7, ≥8), (2) type of pain (spinal cord infiltration or others), (3) HADS total score (≤10, ≥11), (4) treatment setting (inpatient or outpatient), (5) response to gabapentinoids (non-responsive or intolerance due to side effects) and (6) study site.

### Masking {#s2c3}

Patients and clinicians responsible for treatment will be blinded to administration of duloxetine or placebo. Only a clinical trial pharmacist who generate capsules, but is not involved in patient care, will know the allocation and outcomes. All study drugs will be packaged by this pharmacist. Duloxetine (Cymbalta) will be administered with a change in dosage form: the capsules will be covered with a No. 3 capsule of the same material to make an overcapsule.

### Data management, central monitoring and audit {#s2c4}

Evaluations will be performed at four time points: baseline (time of randomisation, T0), the day before the start of treatment (day 0, T1) and 3 days (day 3, T2) and 10 days (day 10, T3) after initiation of treatment. The timing and details of evaluations are given in [table 1](#T1){ref-type="table"}.

###### 

Study procedure and time points for actions and evaluations

  -----------------------------------------------------------------
                               T0\         T1\     T2\     T3\
                               Inclusion   Day 0   Day 3   Day 10
  ---------------------------- ----------- ------- ------- --------
  Consent, randomisation       ○           ―       ―       ―

  NRS for pain                 ○           ○       ○       ○

  Pain Relief Scale            ―           ―       ○       ―

  SF-MPQ-2                     ―           ○       ―       ―

  Opioid consumption           ―           ○       ○       ○

  EORTC QLQ-C15-PAL            ―           ○       ―       ○

  HADS                         ○           ―       ―       ○

  Pain Catastrophizing Scale   ―           ○       ―       ―

  ECOG PS                      ○           ○       ―       ○

  Adverse events               ―           ○       ○       ○
  -----------------------------------------------------------------

ECOG PS, European Cooperative Oncology Group Performance Status; EORTC, European Organisation for Research and Treatment of Cancer; HADS, Hospital Anxiety and Depression Scale; NRS, Numerical Rating Scale; SF-MPQ-2, Short-Form McGill Pain Questionnaire 2.

Once a patient is enrolled or randomised, the study site will make every reasonable effort to follow the patient for the entire study period. Patients will not be allowed to cross over from one group to another group until the end of the study (T3); however, they can choose to leave the study for any reasons at any time without detriment to the provision or quality of their clinical care. The investigators at each study sites will maintain individual records for each patient as source data, which include a copy of informed consent, medical records, laboratory data and other records or notes. All data will be collected by the independent data management centre. The data management centre will oversee the intrastudy data sharing process. The clinical data entry, data management and central monitoring will be performed using the electric data capture VIEDOC 3 (PCG Solutions, Sweden). An interim analysis will not be performed. Also, auditing is not planned in this study.

### Harms {#s2c5}

Investigators must record all AEs in the medical records and web systems. The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) (V.4.0) will be used to grade each AE. All AEs are to be followed up continually during their course up. All severe adverse events must be reported to the institutional review board (IRB) and investigators in all sites and discussed through a FAX. Patients who are enrolled into the study will be treated by healthcare services provided by health insurance.

Measurement tools {#s2d}
-----------------

### Numerical Rating Scale {#s2d1}

The 11-point NRS will be used to measure pain intensity from 0 (no pain) to 10 (worst possible pain), based on average pain in the past 24 hours.[@R24]

### Pain Relief Scale {#s2d2}

A self-assessment will be performed by the patients using the Pain Relief Scale. Patients will determine for themselves the efficacy of analgesics using a 4-point scale of complete relief, a lot of relief, slight relief and no change.

### Short-Form McGill Pain Questionnaire 2 (Japanese version) {#s2d3}

The Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2) will be used to examine differences in effects due to pain mechanisms. The reliability and validity of the Japanese version have been verified.[@R25]

### European Organisation for Research and Treatment of Cancer QLQ-C15-PAL {#s2d4}

European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL will be used for evaluation of patient quality of life. The reliability and validity of the Japanese version have been confirmed.[@R26]

### Hospital Anxiety and Depression Scale {#s2d5}

The Hospital Anxiety and Depression Scale (HADS) will be used for measurement of psychiatric symptoms (anxiety and depression) of patients with a physical disease. HADS is a screening tool that allows assessment based on a small number of items. Its reliability and validity have been verified internationally.[@R27] A HADS score \<20 points as a cut-off for exclusion of patients with cancer with severe depression will be used, based on a previous report.[@R28]

### Pain Catastrophizing Scale {#s2d6}

The severity of cancer-related pain is influenced by engagement of patients in catastrophic thinking, such as 'my pain will undoubtedly never improve'.[@R29] This effect will be measured using the Japanese version of the Pain Catastrophizing Scale (PCS), for which the validity and reliability have been shown.[@R30]

### Common Terminology Criteria for Adverse Events {#s2d7}

The worst grade of an AE during the preceding period will be assessed using the CTCAE V.4.0, Japanese Clinical Oncology Group (JCOG) version. Five AEs of somnolence, dizziness, nausea, palpitations and hypertension will be investigated if they occur at a relatively high frequency. Other AEs may also be assessed.

### Performance Status {#s2d8}

The European Cooperative Oncology Group Performance Status (ECOG PS) system will be used for evaluation of PS by primary physicians.[@R31]

Treatment {#s2e}
---------

### Preintervention treatment {#s2e1}

Opioids (morphine, oxycodone, fentanyl, tapentadol) will be given to all patients. If AEs of gabapentinoids are severe, they will be discontinued or reduced in dose, but if the adverse effects are tolerable but the therapeutic effect is insufficient, gabapentinoids will be administered concomitantly with duloxetine. Pregabalin and gabapentin will be used in the study at the established effective doses of 300 mg and 1800 mg, respectively.[@R14]

### Interventions {#s2e2}

Duloxetine or placebo will be administered for 10 days. Duloxetine (20 mg/day, one capsule) will be taken orally by participants in the intervention group starting after breakfast on day 1. To determine if titration is necessary, pain relief will be evaluated using the Pain Relief Scale on day 3 (T2). Changes in symptoms, AEs and medication compliance will be evaluated. Patients who have 'complete relief' or 'a lot of relief' of pain will continue to receive doses of 20 mg/day from day 4. In all other cases, the dose will be increased to 40 mg/day (two capsules) from day 4. If an intolerable AE such as nausea occurs at 40 mg/day, the dose will be reduced as required. If an intolerable AE occurs at 20 mg/day, the protocol will be discontinued. AEs that may be caused by duloxetine, such as somnolence, dizziness, nausea, palpitations and hypertension, will be evaluated to determine whether duloxetine treatment should be interrupted.

Placebo (22.4 mg lactose in a No. 4 capsule) will be administered to participants in the control group by oral administration (1 capsule/day) starting after breakfast on day 1. To determine if titration is necessary, pain relief will be evaluated using the Pain Relief Scale on day 3 (T2), and changes in symptoms, AEs and medication compliance will be examined. Patients with 'complete relief' or 'a lot of relief' of pain will continue to receive 1 capsule/day from day 4. In all other cases, the dose will be increased to 2 capsules/day from day 4. If an intolerable AE such as nausea occurs at 2 capsules/day, the dose will be reduced as side effects dictate. If there is an intolerable AE at 1 capsule/day, the protocol will be discontinued. To improve adherence to intervention protocols, participants will return the unused tablets at the last visit, and unused tablets will be counted and recorded on the medical records. Currently, there is no specific standard treatment for NP in patients with cancer; placebo is used instead of active control.

### Cotreatments {#s2e3}

Concomitantly administered analgesics such as opioids, non-steroidal anti-inflammatory drugs, acetaminophen or other adjuvant analgesics such as anticonvulsants, antidepressants, antiarrhythmics, N-methyl-D-aspartate receptor antagonists and steroids will not be changed during the follow-up period. In principle, new analgesics will not be started. When nausea occurs during the period of duloxetine administration, use of an antiemetic will be permitted. Currently used immediate-release opioids will be used in cases of breakthrough pain. Immediate-release rescue opioids will be freely permitted without limitation on the number of doses.

Study endpoints {#s2f}
---------------

### Primary endpoint {#s2f1}

The primary endpoint is a comparison of pain intensity (average pain over the previous 24 hours) at T3 (Day 10) measured using NRS in the duloxetine and placebo groups.

### Secondary endpoints {#s2f2}

Efficacy will also be assessed using seven secondary endpoints: the nature of pain using SF-MPQ-2, EORTC QLQ-C15-PAL scores, daily opioid dose, changes in HADS score, degree of catastrophic thinking on PCS, AEs (CTCAE V.4.0-JCOG) and the difference in NRS scores for pain intensity (average over the previous 24 hours) measured at T3 in subgroups of patients who are unresponsive or intolerant to gabapentinoids. Subgroup analyses will be performed on two patient groups; patients unresponsive to gabapentinoids and patients intolerant to gabapentinoids. Additionally, we will calculate percentages of the patients with 33% or 50% decrease.

Statistical considerations {#s2g}
--------------------------

### Statistical hypothesis {#s2g1}

Comparison of the primary endpoint of the NRS score for pain at day 10 (T3) (average pain over the previous 24-hour period) between the duloxetine and placebo groups will be conducted using a one-sided Student's t-test at a significance level of 5% according to the intention-to-treat principle. Point estimates and 90% CIs for the difference between two group means will be calculated.

The secondary endpoints of efficacy (SF-MPQ-2, EORTC QLQ-C15-PAL, HADS, PCS, daily opioid dose and group comparison of average pain on the NRS in the previous 24 hours in patients who are unresponsive or intolerant to gabapentinoids) will be evaluated similarly to the primary endpoint. The distribution of grades of AEs (CTCAE V.4.0-JCOG) and the incidence of AEs of grade 3 or higher and of grade 4 or higher will be determined. A Mantel test will be performed for group comparison.

### Sample size calculation {#s2g2}

The difference between group mean NRS scores for pain in the previous 24 hours on day 10 (T3) is assumed to be 1 point, and the SD of the NRS is taken to be 1.5 points.[@R17] As there was no consensus about the minimal clinically important differences of duloxetine in cancer NP at the planning stage of the study, we decided to adopt a 1-point difference compared with placebo as the clinical significant difference, according to the meta-analysis of neuropathic non-cancer pain.[@R33] During this study periods, Hui *et al* reported that the optimal cut-off was ≥1 point for improvement in cancer pain.[@R34]

Assuming a rate of exclusion of 10%, 35 subjects are needed in each group (70 subjects in total) to achieve a statistical power of 80% with a one-sided significance level of 5%. As our primary interest is to clarify whether duloxetine is more effective than placebo, we adopted a one-sided test.

Ethical issues {#s2h}
--------------

All patients will be required to provide written informed consent. The study will be performed in accordance with the Declaration of Helsinki and the Japanese ethical guidelines for clinical research. The protocol was approved by the IRB at each study site (Osaka: Kindai University Hospital, Kansai Medical University Hospital, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City Medical Center, Izumi Municipal Hospital and Sakai Hospital Kindai University Faculty of Medicine; Tokyo: National Cancer Center Hospital; Chiba: National Cancer Centre Hospital East; Nara: Nara Medical University Hospital; Nagoya: Nagoya University Hospital; Hyogo: Hyogo Prefectural Amagasaki General Medical Center, Kobe University Graduate School of Medicine and Hyogo Prefectural Kakogawa Medical Center; and Fukuoka: National Hospital Organization Kyusyu Cancer Center). This trial has been registered at the UMIN Clinical Trials Registry as UMIN000017647. Modiﬁcations in the study protocol will be communicated to the IRB at each study site as well as the independent data monitoring committee. Each ethics committee or IRB will revise informed consent materials given to participants and adapt according to their own institution's guidelines.

Discussion {#s3}
==========

To our knowledge, there has been no randomised study of the analgesic efficacy of duloxetine in patients with neuropathic cancer pain refractory to opioids and gabapentinoids. In our planned trial, we will use a randomised, double-blind, placebo-controlled design, which is the most appropriate design to demonstrate the efficacy of a new therapy. Our findings using this approach may also allow international recommendations to be updated. We also considered a crossover design, but a parallel design was finally chosen, given that the crossover design has several limitations.[@R35] The crossover design is suitable for patients in a stable condition, but this is not the situation for patients with cancer with NP refractory to opioids and gabapentinoids. We also believe that the treatment might have carryover effects and alter the response to subsequent treatments and that patients may not be in a comparable condition at the start of each treatment period in a crossover trial.

Several issues related to the content of the trial require discussion. There are three major concerns: (i) the heterogeneity of causes of NP, (ii) the choice of the primary endpoint and (iii) the role of depression. To address the heterogeneous causes of NP, we excluded patients with CIPN, but the trial might still be criticised due to combination of peripheral and central NP in one study. Narrower criteria are theoretically possible, but accrual of patients who meet these criteria is likely to be difficult. We thus decided to include both peripheral and central NP in the study, and subgroup analyses will be performed. Second, the primary endpoint is the difference in average pain intensity score at T3 (day 10) between two groups. Although we had acknowledged that some authors recommend worst pain intensity in the last 24 hours as primary endpoints because it satisfies most key recommendations in the draft guidance by the Food and Drug Administration,[@R36] average pain intensity is adopted by many clinical trials about NP,[@R37] including only one placebo-controlled randomised controlled trial (RCT) in patients with cancer with NP.[@R14] Furthermore, to evaluate chronic pain, especially taking into account the nature of NP in this setting, we concluded that it is better to use the 'average pain intensity in the last 24 hours' as the primary endpoint after discussion among the members of the steering committee. Finally, since depression affects the assessment of pain, we excluded patients with depression from the study population for accurate evaluation of the pharmacological effects of duloxetine on pain. Therefore, the planned placebo-controlled, double-blind multicentre RCT will be the first to evaluate the efficacy of pharmacological treatment on well-defined NP in patients with cancer.

Trial status {#s3a}
------------

The enrolment started in July 2015. At the time of manuscript submission (June 2017), two-thirds of patients have participated. We thus expect to complete the recruitment by December 2017.

Confidentially {#s3b}
--------------

Data will be retained in accordance with the Japanese ethical guidelines for clinical research. Participants will be allocated a unique identification (ID) number at entry. The master list linking participant personal information and ID number will be maintained in a separate locked cabinet and password-protected hard drive at each institution. Data will be analysed by ID number only. Records will be retained for 5 years after study completion and then destroyed by the data centre.

Dissemination {#s3c}
-------------

The results of this study will be submitted for publication in international peer-reviewed journals and the key findings presented at conferences. Participants will be informed of the results of the trial by the investigators. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance.
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